Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prior participation in protocol TPL103922 or TPL108390 and completed the Week 24 Follow Up Visit in TPL103922 or TPL108390
Male or female ≥18 years old
Evidence of chronic HCV infection
While participating in TPL103922 or TPL108390, discontinued from study drug due to thrombocytopenia
Appropriate candidate for antiviral therapy with pegylated interferon plus ribavirin
Platelet count \<75,000
Fertile males and females must use two forms of effective contraception during treatment and for 24 weeks after treatment
Ability to understand and comply with the protocol requirements and instructions
Ability to provide written informed consent
You may not be if
Decompensated liver disease
Known hypersensitivity, intolerance, or allergy to interferon, ribavirin, eltrombopag, or their ingredients
History of clinically significant bleeding from oesophageal or gastric varices
History of arterial or venous thrombosis and two or more of the following risk factors: hereditary thrombophilic disorders; hormone replacement therapy; systemic contraception (containing estrogen); smoking; diabetes; hypercholesterolemia; medication for hypertension or cancer
Pre-existing cardiac disease (congestive heart failure Grade III/IV) or arrhythmias known to involve the risk of thromboembolic events (e.g. atrial fibrillation)
Evidence of hepatocellular carcinoma
HIV or Hepatitis B infection
Therapy with anti-neoplastic or immunomodulatory treatment within six months prior to eltrombopag therapy
Malignancy diagnosed or treated within the past five years. Except for localized basal or squamous cell carcinoma treated by local excision or malignancies that were adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival.
Pregnant or nursing women
Men with a female partner who is pregnant
History of alcohol/drug abuse or dependence within six months of the study start unless participating in a controlled rehabilitation programme.
Treatment with an investigational drug or interferon within 30 days or 5 half-lives (whichever is longer) of the screening visit
History or platelet clumping that prevents reliable measurement of platelet counts
Evidence of portal vein thrombosis within three months of baseline visit
